RxDoctor Payments Data

Adam Norwood, DO

Adult Reconstructive Orthopaedic Surgery · Little Rock, ARNPI 1093014136

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Stryker at 59.8% of the total. Reporting peaked in 2024 at $488 and has fallen 56.9% since, to $210 in 2025.

$1,264in general payments, 2019–2025

Across 28 payments — averaging $45.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$756
  • Zimmer Biomet$145
  • Smith+Nephew$114
  • Urgo Medical North America, LLC$74
  • Johnson & Johnson$60
  • Vertex$43
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$1,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$128,831
Medicare patients
186
Services billed
1,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$5,237
Diclofenac Sodium62$1,508
Ondansetron OdtOndansetron77$600
Meloxicam110$415
Pregabalin50$385
Celecoxib24$357
Oxycodone Hcl87$259
Cephalexin67$242
Methocarbamol46$228
Tramadol Hcl119$227
Doxycycline Hyclate21$188
Baclofen11$153
Methylprednisolone20$152
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$130
Dexamethasone73$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$60$5,23711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult reconstructive orthopaedic surgery providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other adult reconstructive orthopaedic surgery in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →